Blood online
Home About Blood Authors Subscriptions Permission Advertising Public Access contact us
 

 
Advanced
Current Issue
First Edition
Future Articles
Archives
Submit to Blood
Search
American Society of Hematology
Meeting Abstracts
Email Alerts

Blood, Vol. 113, Issue 15, 3640-3648, April 9, 2009
This Article
Right arrow Abstract
Right arrow Full Text
Services
Right arrow Email this article to a friend
Right arrow Alert me to new issues of the journal
Right arrow reprints & permissions
Right arrow Rights and Permissions
Citing Articles
Right arrow Citing Articles via CrossRef

C7 is expressed on endothelial cells as a trap for the assembling terminal complement complex and may exert anti-inflammatory function
Blood Bossi et al. 113: 3640

Supplemental materials for: Bossi et al

Files in this Data Supplement:

  • Table S1. Peptides from C7 and vimentin observed in the tryptic digests of the affinity purified protein material (XLS, 876 KB) -
    MM, calculated average molecular mass of the unmodified peptide sequence; z, charge state; ProtProb, ProteiProphet probability; Adj. PepProb, adjusted PeptideProphet probability; Init. PepProb., intial PeptideProphet probability; NTT, number of tryptic termini; #, oxidized methionine.

  • Figure S1. Glycocalix removal did not reduce mC7 expression (JPG, 55.4 KB) -
    HUVECs were treated with the mixture of the heparinase I, II and III (each at 3 × 10−2 Units/ml) for 2 h at 37°C to remove cell surface glycosaminoglycans. (A) The presence of residual cell-bound C7 and CD31, used as control of an integral membrane protein, was revealed by a fluorescence reader Infinite200 (TECAN) using FITC-labeled antibodies.The removal of glycocalix was checked by the failure of FITC-Ulex europaeus agglutinin I (UEA-I) to bind to treated cells. Values are mean ± SD of triplicate determinations of 3 separate experiment. *P <.05. (B). FACS analysis of heparinase-treated (black line) and untreated cells (dotted line) for the expression of mC7. One of 3 different experiments with similar results is shown.





  • Figure S2. SDS-resistant polyC9 in mTCC (JPG, 96.6 KB) -
    Native C9 (track 1) or EC lysate collected after the assembly of mTCC were analyzed by Western blot with polyclonal anti-C9 (1:100) followed by AP-conjugated anti-goat antibodies. Data are representative of three independent experiments.





  • Figure S3. mC7 expression is increased by pro-inflammatory cytokines (JPG, 44.2 KB) -
    HUVECs were stimulated with IL-1α (10 U/ml) , IFN-γ (100 U/ml), or TNF-α (100 ng/ml) for 48 h and the presence of mC7 was evaluated by ELISA. Values are mean ± SD of triplicate determinations of 3 separate experiment. *P <.05 versus basal value.





This Article
Right arrow Abstract
Right arrow Full Text
Services
Right arrow Email this article to a friend
Right arrow Alert me to new issues of the journal
Right arrow reprints & permissions
Right arrow Rights and Permissions
Citing Articles
Right arrow Citing Articles via CrossRef

 click for free articles
home about blood authors subscriptions permissions advertising public access contact us
  Copyright © 2009 by American Society of Hematology         Online ISSN: 1528-0020